What the research says about teriparatide

What teriparatide is

Teriparatide is described in the literature as recombinant human parathyroid hormone (1-34), abbreviated rhPTH(1-34), and it is classed as an anabolic (bone-forming) agent rather than an antiresorptive one ^[1]. A 2008 review notes that once-daily subcutaneous teriparatide improved bone mineral density and altered bone-formation and bone-resorption markers in women with postmenopausal osteoporosis, in men with idiopathic or hypogonadal osteoporosis, and in patients with glucocorticoid-induced osteoporosis ^[1].

It is marketed as an approved pharmaceutical (Forteo/Forsteo) for people with osteoporosis at high risk of fracture ^[1]. Material sold by third-party research-chemical vendors is not the approved pharmacy product and is offered for laboratory and research use only.

What the human research has measured

Teriparatide's effects on bone density and fractures have been measured in multiple randomized controlled trials and pooled in meta-analyses. A 2024 systematic review and meta-analysis of head-to-head randomized trials in patients not previously treated with bisphosphonates (23 trials, 6680 patients) reported that teriparatide was superior to bisphosphonates in reducing fracture risk (risk ratio 0.61, 95% CI 0.51 to 0.74) and increased femoral-neck, total-hip, and lumbar-spine bone mineral density ^[3].

A 2025 systematic review and network meta-analysis of 17 studies reported that teriparatide and the related agent abaloparatide both reduced vertebral and non-vertebral fractures versus placebo, with abaloparatide showing an advantage over teriparatide for non-vertebral fractures (odds ratio 0.87, 95% CI 0.80 to 0.95) and hip fractures (odds ratio 0.81, 95% CI 0.71 to 0.93) ^[2]. A 2024 meta-analysis versus oral bisphosphonates reported greater percentage increases in lumbar-spine bone mineral density with teriparatide ^[4].

In an 18-month randomized, double-blind trial in glucocorticoid-induced osteoporosis, lumbar-spine bone mineral density increased more in the teriparatide group than in the alendronate group (about 7.2% versus 3.4%), and fewer new vertebral fractures occurred in the teriparatide group (0.6% versus 6.1%), while non-vertebral fractures were similar between groups (5.6% versus 3.7%) ^[6]. A separate meta-analysis of five trials reported a reduced risk of new or worsening back pain with teriparatide (relative risk 0.66, 95% CI 0.55 to 0.80) ^[5], and a quantitative-CT sub-analysis reported gains in trabecular bone of the vertebra ^[7].

What the trials report on safety and adverse events

The teriparatide trials measured adverse events alongside bone outcomes. The 2024 head-to-head meta-analysis reported that teriparatide did not increase the overall incidence of adverse events versus bisphosphonates (risk ratio 0.92, 95% CI 0.79 to 1.08) ^[3], and the 2025 network meta-analysis reported acceptable safety with no increased cardiovascular risk for the PTH1-receptor agonists ^[2].

Trial-level data describe specific signals. In postmenopausal women with normal or impaired renal function, teriparatide was associated with an increased incidence of transient post-dose serum calcium above the upper limit of normal and with elevated uric acid, without a signal for increased gout, arthralgia, or kidney-stone events ^[8]. Elevated serum calcium was also more frequent with teriparatide than alendronate in the glucocorticoid trial ^[6].

Post-marketing pharmacovigilance describes rarer events. A case series drawing on FDA adverse-event reports reported 12 cases of teriparatide-associated calciphylaxis (a rare, potentially fatal small-vessel calcification disorder), with a median time-to-onset of about 3.5 months and all cases carrying multiple additional risk factors ^[9]. A single case report described intermittent atrial tachycardia coinciding with teriparatide injections ^[10].

These are measured rates and reports within an approved, pharmaceutical-grade medicine studied largely in people with osteoporosis, not a safety guarantee and not a prediction for any individual. Material sold by research-chemical vendors is not that regulated product. This is not medical advice; consult a qualified professional and read the trials directly.

How strong is the evidence

Because teriparatide's effects on bone density and fracture risk have been measured in multiple randomized controlled trials and pooled in systematic reviews and meta-analyses, the evidence base is characterized as strong relative to the preclinical-only peptides in this library ^[2][3][5]. "Strong" describes the quality and design of the published trials, not an endorsement, and the scope is specific: nearly all of this evidence is in people with osteoporosis at high fracture risk ^[1][2].

Nothing here is dosing, medical, or safety guidance. Read the studies themselves and consult a qualified professional. This page is a map to the evidence, not a recommendation.